Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil.
Front Endocrinol (Lausanne). 2022 Jul 8;13:896378. doi: 10.3389/fendo.2022.896378. eCollection 2022.
Pre-existing conditions, such as age, hypertension, obesity, and diabetes, constitute known risk factors for severe COVID-19. However, the impact of prediabetes mellitus (PDM) on COVID-19 severity is less clear. This study aimed to evaluate the influence of PDM in the acute and long-term phases of COVID-19.
We compared inflammatory mediators, laboratory and clinical parameters and symptoms in COVID-19 patients with prediabetes (PDM) and without diabetes (NDM) during the acute phase of infection and at three months post-hospitalization.
Patients with PDM had longer hospital stays and required intensive care unit admission more frequently than NDM. Upon hospitalization, PDM patients exhibited higher serum levels of interleukin 6 (IL-6), which is related to reduced partial pressure of oxygen (PaO) in arterial blood, oxygen saturation (SpO) and increased COVID-19 severity. However, at three months after discharge, those with PDM did not exhibit significant alterations in laboratory parameters or residual symptoms; however, PDM was observed to influence the profile of reported symptoms.
PDM seems to be associated with increased risk of severe COVID-19, as well as higher serum levels of IL-6, which may constitute a potential biomarker of severe COVID-19 risk in affected patients. Furthermore, while PDM correlated with more severe acute-phase COVID-19, no long-term worsening of sequelae was observed.
既往疾病，如年龄、高血压、肥胖和糖尿病，构成了 COVID-19 重症的已知危险因素。然而，糖尿病前期（PDM）对 COVID-19 严重程度的影响尚不清楚。本研究旨在评估 PDM 在 COVID-19 急性和长期阶段的影响。
我们比较了 COVID-19 合并和不合并糖尿病（NDM）患者在感染急性期和住院后 3 个月的炎症介质、实验室和临床参数以及症状。
与 NDM 相比，PDM 患者的住院时间更长，更需要入住重症监护病房。住院时，PDM 患者的血清白细胞介素 6（IL-6）水平较高，与动脉血氧分压（PaO）降低、血氧饱和度（SpO）降低和 COVID-19 严重程度增加有关。然而，出院后 3 个月，PDM 患者的实验室参数或残留症状无明显改变；然而，PDM 影响了报告症状的特征。
PDM 似乎与 COVID-19 重症风险增加以及血清 IL-6 水平升高有关，这可能是影响患者 COVID-19 重症风险的潜在生物标志物。此外，虽然 PDM 与更严重的急性 COVID-19 相关，但未观察到长期后遗症恶化。
